← Issue №14/ week of Oct 4, 2026/IBD

Long-term clinical outcomes of stem cell-based interventions in Crohn's-related perianal fistula: A systematic review and meta-analysis.

From GI Signals issue №14: what this paper found, what it changes, and where it sits against the current standard of care, reviewed by Simon Mathews, MD.

IBD meta analysis · n=750 · Oct 1, 2026 · Colorectal Disease · IF 3.2

Long-term clinical outcomes of stem cell-based interventions in Crohn's-related perianal fistula: A systematic review and meta-analysis.

New evidenceCrohn's diseaseperianal diseasemeta-analysissystematic review
Clinical takeawayConsider mesenchymal stem cell therapy for Crohn's disease-associated perianal fistulas refractory to conventional treatment, as it achieves durable closure in approximately two-thirds of patients with a favorable safety profile.
What it foundPooled long-term healing rate with stem cell-based therapy was 59% (95% CI, 51%-67%) in RCTs, compared to conventional treatment.
ContextConfirms stem cell-based therapy as a viable long-term option for refractory Crohn's-related perianal fistulas in patients who have failed conventional treatment, extending prior evidence of short-term efficacy.
No standard claimed for this paper

Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.

Heidari M … Alatab S · Colorectal Disease : the Official Journal of the Association of Coloproctology of Great Britain and Ireland · IF 3.2 · PubMed ↗Permalink
← Read the whole of issue №14 Every paper GI Signals surfaces gets a page like this one. All issues